- Company
- Commercialization of 3rd new P-CAB drug near
- by Kim, Jin-Gu Jun 8, 2023 05:33am
- The launch of the third product is imminent in the P-CAB (potassium competitive acid blocker) class gastroesophageal reflux disease treatment market that has grown to post sales of KRW 140 billion a year. With Onconic Therapeutics, a new drug development subsidiary of Jeil Pharmaceutical, filing an application for the marketing authoriz
- Company
- Yuhan presents 4 studies at ASCO...builds reliability
- by Jung, Sae-Im Jun 8, 2023 05:33am
- Yuhan Corp’s EGFR-targeting anticancer drug ‘Leclaza’ has started to accumulate data for the international stage. At the ‘2023 ASCO Annual Meeting (ASCO 2023)’ that was held on the 2nd (local time), Yuhan Corp made 4 poster presentations on studies related to its Leclaza, including one long-term follow-up study. With the results of
- Company
- Novartis counterattacks against Celltrion / a patent lawsuit
- by Kim, Jin-Gu Jun 7, 2023 09:47pm
- Novartis is investigating Celltrion for patent infringement of its biosimilar Xolair, asthma, and urticaria treatment. According to the pharmaceutical industry on the 2nd, Novartis filed two claims against Celltrion on the 1st. A proactive trial to confirm the scope of rights is to ask the Intellectual Property Trial and Appeals Board to acc
- Company
- Kwangdong wins patent lawsuit against Ibrance in reverse
- by Kim, Jin-Gu Jun 7, 2023 05:38am
- As Kwangdong Pharmaceutical succeeded in reversing the second trial of the patent lawsuit against Ibrance, it boarded the last train for generic exclusivity. As a result, Ibrance's generic for exclusivity is owned by three companies, including Daewoong Pharmaceutical and Shinpoong Pharmaceutical, which won in the first trial, and Kwangdong P
- Company
- Sales of anti-cancer drug 'Taxol' increases by 53%
- by Kim, Jin-Gu Jun 7, 2023 05:38am
- Sales of the original Paclitaxel anti-cancer drug 'Taxol' increased 53% in one year. This change has seemed to have occurred as Boryung took over domestic sales from the beginning of this year. According to IQVIA, a pharmaceutical market research institute, on the 2nd, Taxol's sales in the first quarter was KRW 2.9 billion. This is a 53
- Company
- Pfizer's ADC Mylotarg can be prescribed by Big 5
- by Eo, Yun-Ho Jun 7, 2023 05:38am
- Pfizer's new ADC drug, Mylotarg, has settled in a Big 5 general hospital. According to the related industry, Pfizer Korea's acute myeloid leukemia (AML) Mylotarg is a drug for medical institutions such as SMC, SNUH, Seoul St. Mary's Hospital, AMC, Shinchon Severance Hospital, as well as advanced general hospitals such as the National Cancer
- Company
- 'Saxenda' continues to dominate weight-loss market
- by Kim, Jin-Gu Jun 7, 2023 05:38am
- 'Saxenda (Liraglutide)' is further strengthening its dominance in the obesity treatment market. In the first quarter, it recorded sales of KRW 15.9 billion, 53% increase from the previous year, more than doubling the gap with the runner-up product, 'Qsymia (Phentermine+Topiramate).' However, it remains to be seen how much longer Saxenda'
- Company
- Interleukin inhibitors Cosentyx·Tremfya busy extending reim
- by Eo, Yun-Ho Jun 5, 2023 05:37am
- News of reimbursement extensions granted for interleukin inhibitors is continuing in Korea. According to industry sources, the scope of reimbursement for Novartis Korea's IL-17A inhibitor 'Cosentyx UnoReady Pen' 300mg/2mL, and Janssen Korea's IL-23 inhibitor ‘Tremfya (guselkumab)' have been extended since last month, and the 1st of this
- Company
- Forxiga will maintain its price for 10 months in KOR
- by Jung, Sae-Im Jun 2, 2023 05:38am
- The prices of AstraZeneca’s SGLT-2 inhibitor ‘Forxiga (dapagliflozin)’ and combination drug ‘Xigduo’ will stay as is until February next year. On the 1st, the Seoul Administrative Court’s 1st Administrative Division accepted the suspension of execution filed by AstraZeneca against the Ministry of Health and Welfare to cancel the drug p
- Company
- BMS and Gilead compete tightly in HBV drug market in KOR
- by Nho, Byung Chul Jun 2, 2023 05:38am
- BMS’s Baraclude and Gilead Science’s Viread are fiercely competing in the KRW 200 billion original hepatitis B treatment market. Based on drug distribution results, sales of Baraclude and Viread, the No.1 and No.2 products in the HBV market in 2022, were tallied at KRW 69.5 billion and KRW 62.8 billion, respectively. Just last yea
